Drug Profile
ARI 2243
Alternative Names: ARI-2243Latest Information Update: 04 Apr 2016
Price :
$50
*
At a glance
- Originator Arisaph Pharmaceuticals
- Class Antihyperglycaemics; Small molecules
- Mechanism of Action Dipeptidyl peptidase 4 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 04 Apr 2016 No development reported - Phase-I for Type-2 diabetes mellitus (In volunteers) in USA (PO)
- 10 Jun 2008 Phase-I clinical trials in Type-2 diabetes mellitus in USA (PO)
- 10 Jun 2008 Preclinical pharmacodynamics data in Type-2 diabetes presented at the 68th Scientific Sessions of the American Diabetes Association (ADA-2008) ,